Publications by authors named "David Jayabalan"

35 Publications

Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function.

Front Cell Dev Biol 2020 17;8:605989. Epub 2020 Dec 17.

Jiangsu Key Laboratory of Neuropsychiatric Diseases, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.

View Article and Find Full Text PDF
December 2020

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.

Blood Adv 2019 02;3(4):603-611

Division of Hematology/Oncology, Department of Medicine, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY.

View Article and Find Full Text PDF
February 2019

Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.

Leuk Lymphoma 2014 Dec 25;55(12):2842-9. Epub 2014 Mar 25.

Center of Excellence for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital , New York, NY , USA.

View Article and Find Full Text PDF
December 2014

IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.

Mod Pathol 2014 Mar 13;27(3):375-81. Epub 2013 Sep 13.

Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA.

View Article and Find Full Text PDF
March 2014

Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.

Clin Cancer Res 2013 Mar 28;19(6):1534-46. Epub 2013 Jan 28.

Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York 10021, USA.

View Article and Find Full Text PDF
March 2013

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.

Blood 2013 Mar 8;121(11):1982-5. Epub 2013 Jan 8.

Division of Hematology and Medical Oncology, Department of Medicine, Myeloma Center, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY 10021, USA.

View Article and Find Full Text PDF
March 2013

Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.

Br J Haematol 2008 Dec 16;143(5):654-60. Epub 2008 Oct 16.

Department of Medicine, Division of Hematology and Medical Oncology, Center of Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital-Cornell Medical Center, New York, NY 10021, USA.

View Article and Find Full Text PDF
December 2008

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.

Biol Blood Marrow Transplant 2008 Jul;14(7):795-8

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital-Cornell Medical Center, New York, New York 10021, USA.

View Article and Find Full Text PDF
July 2008